What is KAPA (KAPA) stock price today?

KAPA (KAPA) is currently trading at $0.30, down 3.2% today.

What is KAPA P/E ratio?

KAPA's P/E ratio is -1.70. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is KAPA return on equity (ROE)?

KAPA's return on equity (ROE) is -83.33%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is KAPA's market cap?

KAPA has a market capitalization of $6.42M.

ASE · Biotechnology

KAPA (KAPA) Stock

$0.30 -3.20% ASE: KAPA Healthcare

Valuation

Metric	Value
Price	$0.30
Market Cap	$6.42M
P/E Ratio	-1.70
P/B Ratio	1.83
P/S Ratio	0.00
EPS (TTM)	$-0.30
52-Week High	$2.11
52-Week Low	$0.28
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-83.33%
ROA	-71.43%
ROCE	-85.71%
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Debt/Equity	0.00
Current Ratio	10.31

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$0	$0	$0	$0	$0
Operating Profit	$-2.0M	$-1.0M	$-2.0M	$-2.0M	$-6.0M
Net Profit	$-2.0M	$-1.0M	$-2.0M	$-3.0M	$-5.0M
EPS	$-0.17	$-0.10	$-0.17	$-0.23	$-0.30
Op Margin	—	—	—	—	—

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$1.0M	$1.0M	$1.0M	$6.0M	$7.0M
Total Liabilities	$2.0M	$2.0M	$3.0M	$1.0M	$0
Cash	$0	$0	$0	$1.0M	$4.0M
Borrowings	$0	$1.0M	$1.0M	$0	$0

Latest News

Kairos Pharma Collaborates With Bayer to Assess Prostate Cancer Treatment Combination MT Newswires · Jul 22, 2026 Kairos Pharma Announces Strategic Collaboration with Bayer to Enhance XOFIGO Activity in Metastatic Prostate Cancer Business Wire · Jul 22, 2026 CEO.CA's Inside the Boardroom: Kairos Pharma Might Change Cancer Treatment Forever TMX Newsfile · Jul 15, 2026 Kairos Pharma Reports Breakthrough Interim Safety Data in Phase 1 Trial of ENV-105 in EGFR-Mutated Lung Cancer Patients — Targeting a $10 Billion Drug Resistance Market Business Wire · Jul 15, 2026 All You Need to Know About Kairos Pharma, Ltd. (KAPA) Rating Upgrade to Buy Zacks · Jul 2, 2026

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$0	$0	$0	$-4.0M	$-3.0M
Investing Cash Flow	$0	$0	$0	$0	$0
Financing Cash Flow	$0	$0	$0	$0	$4.0M
Net Cash Flow	$0	$0	$0	$1.0M	$3.0M
Free Cash Flow	$0	$0	$0	$-4.0M	$-3.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	—
EV / EBITDA	—
FCF Yield	-26.63%
Quick Ratio	10.31
Interest Coverage	—
Return 1Y	-72.82%
Return 3Y	—
Return 5Y	—

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
ALLR	$1.39	-0.71%	-1.91	$22.12M	0.00%
BCTX	$3.53	+1.73%	-0.04	$6.65M	0.00%
CASICASI Pharmaceuticals, Inc.	$0.15	+3.08%	-0.07	$2.33M	0.00%
CING	$4.52	-2.59%	-1.08	$25.34M	0.00%
CLSDClearside Biomedical, Inc.	$0.41	+0.00%	-0.11	$2.15M	0.00%

About KAPA

KAPA is led by CEO John S. Yu, employs 1 people, headquartered in US, publicly traded since 2024.

KAPA stock trades at $0.30 with a market capitalization of $6.42M. The stock is valued at a price-to-earnings (P/E) ratio of -1.70, price-to-book of 1.83, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.28 and $2.11, and currently trades 85.8% below its 52-week high.

On profitability, KAPA generates a return on equity (ROE) of -83.33%, return on capital employed of -85.71%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks All stock screens

Run Stock Screener Investing Guides